Amarin announced that Israel’s Ministry of Health, MOH, Pharmaceuticals Division has granted regulatory approval to VAZKEPA. The MOH issued its approval of VAZKEPA to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides and either established cardiovascular disease or diabetes and at least one other cardiovascular risk factor. "The regulatory approval of VAZKEPA in Israel marks continued progress in our effort to bring this product to patients with residual cardiovascular risk around the world," said Steven Ketchum, PhD., President, Research & Development and Chief Scientific Officer, Amarin. "We are proud of this important milestone in that effort, and that patients in Israel may soon be able to access this important therapeutic option to address their residual cardiovascular risk." Amarin has partnership discussions underway in this territory and will be preparing for potential pricing and reimbursement in Israel beginning in 2024.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AMRN: